摘要
目的:对照分析小剂量和常规剂量化疗药物经动脉化疗栓塞术(TACE)对肝细胞癌(HCC)患者血清肝纤维化指标和疗效的影响。方法:对50例HCC患者行TACE,其中小剂量组(n=25)给予小剂量化疗药物,常规剂量组(n=25)给予常规剂量化疗药物。分别检测患者TACE术前、术后7 d血清透明质酸(HA)、人Ⅲ型前胶原(hPC-Ⅲ)、层黏连蛋白(LN)、Ⅳ型前胶原(Ⅳ-C),同时观察近期客观疗效和生存期。结果:TACE术前血清肝纤维化指标两组间均无显著性差异,常规剂量组术后各项指标均明显高于术前(P〈0.05),小剂量组术后各项指标与术前比均无显著性差异(P〉0.05)。术后两组间差值比较出现显著性差异(P〈0.01)。小剂量组与常规剂量组中位生存期分别为19.2个月(95%C I,10-31个月)、18.5个月(95%C I,8-28个月),两组的1和2年生存率分别为60.9%、40.1%和58.8%、39.5%,无显著性差异(P〉0.05)。结论:应用小剂量化疗药物行TACE术治疗肝癌可能减轻患者术后早期肝纤维化程度,且对客观疗效和生存期无影响。
Objective: To study the changes of serum fibrosis indicators and therapeutic effects after transcatheter arterial chemoembolization (TACE) with low-and conventional-dose chemotherapeutic agents in hepatocellular carcinoma (HCC). Methods:Fifty patients with HCC underwent TACE with low-dose anticancer agent in Group A (n = 25) and at conventional-dose in Group B (n = 25). Four ser- um fibrosis indicators, hyaluronic acid (HA), human procollagen type-HI (hPC-111 ), laminin (LN) and collagen type-IV ( IV-C), were assessed before and 7 days after TACE. The therapeutic effects and survival time were compared respectively. Results:There were no significant differences between the two groups in the four indicators before TACE. After TACE, the concentrations of the four serum indicators were increased significantly in Group B ( P 〈0. 05 ), but not significantly different from preoperation in Group A ( P 〉 0.05 ). Significant differences were observed in differential value between the two groups after TACE (P 〈0.01 ), butnot in the median survival period and overall survival rate at 1 and 2 years ( P 〉 0.05 ). Conclusion : TACE with low-dose anticancer agents may reduce the progress of liver fibrosis and have no influence on median survival time in HCC.
出处
《医学研究生学报》
CAS
2007年第9期957-960,共4页
Journal of Medical Postgraduates
基金
江苏省六大人才高峰基金资助项目(批准号:2005A5)
关键词
肝细胞癌
化疗栓塞术
肝纤维化
中位生存期
Hepatocellular carcinoma
Chemoembolization
Liver fibrosis
Median survival period